• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2016 The Regional Health Technology Assessment Centre (HTA-centrum) Surgical treatment of gallbladder cancer
2016 The Regional Health Technology Assessment Centre (HTA-centrum) Positron emission tomography and computed tomographic imaging prior to radiotherapy for lung cancer
2016 The Regional Health Technology Assessment Centre (HTA-centrum) Positron emission tomography and computed tomographic imaging prior to radiotherapy for anal cancer
2016 The Regional Health Technology Assessment Centre (HTA-centrum) Does salpingectomy reduce the risk of ovarian cancer?
2016 The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Ataluren (expiry of the deadline)]
2016 National Institute for Health and Care Excellence (NICE) Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. NICE technology appraisal guidance 375
2016 National Institute for Health and Care Excellence (NICE) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. NICE technology appraisal guidance 377
2016 National Institute for Health and Care Excellence (NICE) Ramucirumab for treating advanced gastric cancer or gastrooesophageal junction adenocarcinoma previously treated with chemotherapy. NICE technology appraisal guidance 378
2016 National Institute for Health and Care Excellence (NICE) Nintedanib for treating idiopathic pulmonary fibrosis. NICE technology appraisal guidance 379
2016 National Institute for Health and Care Excellence (NICE) Panobinostat for treating multiple myeloma after at least 2 previous treatments. NICE technology appraisal guidance 380
2016 National Institute for Health and Care Excellence (NICE) Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal). NICE technology appraisal guidance 382
2016 National Institute for Health and Care Excellence (NICE) Nivolumab for treating advanced (unresectable or metastatic) melanoma. NICE technology appraisal guidance 384
2016 National Institute for Health and Care Excellence (NICE) Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. NICE technology appraisal guidance 385
2016 National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis. NICE technology appraisal guidance 386
2016 National Institute for Health and Care Excellence (NICE) Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. NICE technology appraisal guidance 387
2016 National Institute for Health and Care Excellence (NICE) Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 388
2016 National Institute for Health and Care Excellence (NICE) Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer. NICE technology appraisal guidance 389
2016 National Institute for Health and Care Excellence (NICE) Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes. NICE technology appraisal guidance 390
2016 National Institute for Health and Care Excellence (NICE) Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel. NICE technology appraisal guidance 391
2016 National Institute for Health and Care Excellence (NICE) Adalimumab for treating moderate to severe hidradenitis suppurativa. NICE technology appraisal guidance 392
2016 National Institute for Health and Care Excellence (NICE) Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. NICE technology appraisal guidance 393
2016 National Institute for Health and Care Excellence (NICE) Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. NICE technology appraisal guidance 394
2016 National Institute for Health and Care Excellence (NICE) Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer. NICE technology appraisal guidance 395
2016 National Institute for Health and Care Excellence (NICE) Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma. NICE technology appraisal guidance 396
2016 National Institute for Health and Care Excellence (NICE) Lumacaftorivacaftor for treating cystic fibrosis homozygous for the F508del mutation. NICE technology appraisal guidance 398
2016 National Institute for Health and Care Excellence (NICE) Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts. NICE technology appraisal guidance 399
2016 National Institute for Health and Care Excellence (NICE) Nivolumab in combination with ipilimumab for treating advanced melanoma. NICE technology appraisal guidance 400
2016 National Institute for Health and Care Excellence (NICE) Bosutinib for previously treated chronic myeloid leukaemia. NICE technology appraisal guidance 401
2016 National Institute for Health and Care Excellence (NICE) Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin. NICE technology appraisal guidance 402
2016 National Institute for Health and Care Excellence (NICE) Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 403
2016 National Institute for Health and Care Excellence (NICE) Degarelix for treating advanced hormone-dependent prostate cancer. NICE technology appraisal guidance 404
2016 National Institute for Health and Care Excellence (NICE) Trifluridine-tipiracil for previously treated metastatic colorectal cancer. NICE technology appraisal guidance 405
2016 National Institute for Health and Care Excellence (NICE) Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 406
2016 National Institute for Health and Care Excellence (NICE) Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors. NICE technology appraisal guidance 407
2016 National Institute for Health and Care Excellence (NICE) Pegaspargase for treating acute lymphoblastic leukaemia. NICE technology appraisal guidance 408
2016 National Institute for Health and Care Excellence (NICE) Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion. NICE technology appraisal guidance 409
2016 National Institute for Health and Care Excellence (NICE) Talimogene laherparepvec for treating unresectable metastatic melanoma. NICE technology appraisal guidance 410
2016 National Institute for Health and Care Excellence (NICE) Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer. NICE technology appraisal guidance 411
2016 National Institute for Health and Care Excellence (NICE) Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases. NICE technology appraisal guidance 412
2016 National Institute for Health and Care Excellence (NICE) Elbasvirgrazoprevir for treating chronic hepatitis C. NICE technology appraisal guidance 413
2016 National Institute for Health and Care Excellence (NICE) Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma. NICE technology appraisal guidance 414
2016 National Institute for Health and Care Excellence (NICE) Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor. NICE technology appraisal guidance 415
2016 National Institute for Health and Care Excellence (NICE) Nivolumab for previously treated advanced renal cell carcinoma. NICE technology appraisal guidance 417
2016 National Institute for Health and Care Excellence (NICE) Dapagliflozin in triple therapy for treating type 2 diabetes. NICE technology appraisal guidance 418
2016 National Institute for Health and Care Excellence (NICE) Apremilast for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 419
2016 National Institute for Health and Care Excellence (NICE) Ticagrelor for preventing atherothrombotic events after myocardial infarction. NICE technology appraisal guidance 420
2016 National Institute for Health and Care Excellence (NICE) Everolimus with exemestane for treating advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 421
2016 National Institute for Health and Care Excellence (NICE) Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 422
2016 National Institute for Health and Care Excellence (NICE) Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens. NICE technology appraisal guidance 423
2016 National Institute for Health and Care Excellence (NICE) Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer. NICE technology appraisal guidance 424
2016 National Institute for Health and Care Excellence (NICE) Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia. NICE technology appraisal guidance 425
2016 National Institute for Health and Care Excellence (NICE) Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia. NICE technology appraisal guidance 426
2016 National Institute for Health and Care Excellence (NICE) Extracorporeal shockwave therapy for Achilles tendinopathy. NICE interventional procedures guidance 571
2016 National Institute for Health and Care Excellence (NICE) Radiation therapy for early Dupuytren's disease. NICE interventional procedures guidance 573
2016 National Institute for Health and Care Excellence (NICE) Epiduroscopic lumbar discectomy through the sacral hiatus for sciatica. NICE interventional procedures guidance 570
2016 National Institute for Health and Care Excellence (NICE) Endoscopic transluminal pancreatic necrosectomy. NICE interventional procedures guidance 567
2016 National Institute for Health and Care Excellence (NICE) Percutaneous insertion of craniocaudal expandable implants for vertebral compression fracture. NICE interventional procedures guidance 568
2016 National Institute for Health and Care Excellence (NICE) Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity. NICE interventional procedures guidance 569
2016 National Institute for Health and Care Excellence (NICE) Single-incision short sling mesh insertion for stress urinary incontinence in women. NICE interventional procedures guidance 566
2016 National Institute for Health and Care Excellence (NICE) Miniature lens system implantation for advanced age-related macular degeneration. NICE interventional procedures guidance 565
2016 National Institute for Health and Care Excellence (NICE) Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation. NICE interventional procedures guidance 563
2016 National Institute for Health and Care Excellence (NICE) Microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee defects. NICE interventional procedures guidance 560
2016 National Institute for Health and Care Excellence (NICE) Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting. NICE interventional procedures guidance 561
2016 National Institute for Health and Care Excellence (NICE) Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules. NICE interventional procedures guidance 562
2016 National Institute for Health and Care Excellence (NICE) Endovenous mechanochemical ablation for varicose veins. NICE interventional procedures guidance 557
2016 National Institute for Health and Care Excellence (NICE) Microwave ablation for treating liver metastases. NICE interventional procedures guidance 553
2016 National Institute for Health and Care Excellence (NICE) Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. NICE interventional procedures guidance 554
2016 National Institute for Health and Care Excellence (NICE) Percutaneous interlaminar endoscopic lumbar discectomy for sciatica. NICE interventional procedures guidance 555
2016 National Institute for Health and Care Excellence (NICE) Percutaneous transforaminal endoscopic lumbar discectomy for sciatica. NICE interventional procedures guidance 556
2016 National Institute for Health and Care Excellence (NICE) Corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis. NICE interventional procedures guidance 551
2016 National Institute for Health and Care Excellence (NICE) Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine. NICE interventional procedures guidance 552
2016 National Institute for Health and Care Excellence (NICE) Endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia. NICE interventional procedures guidance 550
2016 National Institute for Health and Care Excellence (NICE) Angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction. NICE interventional procedures guidance 546
2016 National Institute for Health and Care Excellence (NICE) Mechanical clot retrieval for treating acute ischaemic stroke. NICE interventional procedures guidance 548
2016 National Institute for Health and Care Excellence (NICE) Normothermic extracorporeal preservation of hearts for transplantation following donation after brainstem death. NICE interventional procedures guidance 549
2016 National Institute for Health and Care Excellence (NICE) Percutaneous coblation of the intervertebral disc for low back pain and sciatica. NICE interventional procedures guidance 543
2016 National Institute for Health and Care Excellence (NICE) Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica. NICE interventional procedures guidance 544
2016 National Institute for Health and Care Excellence (NICE) Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. NICE interventional procedures guidance 545
2016 National Institute for Health and Care Excellence (NICE) XprESS multi sinus dilation system for treating chronic sinusitis. NICE medical technologies guidance 30
2016 National Institute for Health and Care Excellence (NICE) Spectra Optia for automatic red blood cell exchange in people with sickle cell disease. NICE medical technologies guidance 28
2016 National Institute for Health and Care Excellence (NICE) SepsiTest assay for rapidly identifying bloodstream bacteria and fungi. NICE diagnostics guidance 20
2016 National Institute for Health and Care Excellence (NICE) High-throughput non-invasive prenatal testing for fetal RHD genotype. NICE diagnostics guidance 25
2016 National Institute for Health and Care Excellence (NICE) ImmunoCAP ISAC 112 for multiplex allergen testing. NICE diagnostics guidance 24
2016 National Institute for Health and Care Excellence (NICE) Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits). NICE diagnostics guidance 22
2016 Canary Health Service [Fetal DNA analysis in maternal blood for the detection of trisomies 21, 18 and 13]
2016 Canary Health Service [Spanish society's willingness to pay for a quality-adjusted life year]
2016 Canary Health Service [Effectiveness and cost-effectiveness of surveillance programs to prevent hip dislocation in cerebral palsy]
2016 Canary Health Service [Effectiveness, safety and cost-effectiveness of the flash interstitial fluid glucose monitoring system (FreeStyle Libre®) for type 1 and 2 diabetes mellitus]
2016 Canary Health Service [Indications, safety, effectiveness and cost-effectiveness of noninvasive brain stimulation in the treatment of mental disorders]
2016 Canary Health Service [Extracorporeal membrane oxygenation (ECMO) in patients with advanced heart failure or cardiogenic shock]
2016 Canary Health Service [Patient participation in health technology assessment: methodological manual]
2016 Canary Health Service [Safety, clinical effectiveness and cost-effectiveness of stereo-electroencephalography in epilepsy surgery]
2016 Canary Health Service [Prognostic genomic tests for localized prostate cancer]
2016 Health Information and Quality Authority (HIQA) A guide to health technology assessment at HIQA
2016 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation and approach to fibromyalgia: update of scientific evidence]
2016 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation and approach to chronic fatigue syndrome: update of scientific evidence]
2015 NIHR Health Technology Assessment programme Computed tomographic colonography compared with colonoscopy or barium enema for diagnosis of colorectal cancer in older symptomatic patients: two multicentre randomised trials with economic evaluation (the SIGGAR trials)
2015 NIHR Health Technology Assessment programme A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial
2015 NIHR Health Technology Assessment programme A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)
2015 NIHR Health Technology Assessment programme Clinical effectiveness and cost-effectiveness of open and arthroscopic rotator cuff repair [the UK Rotator Cuff Surgery (UKUFF) randomised trial]